Facial Wrinkles Clinical Trial
Official title:
A Prospective, Multicenter, Single Arm Clinical Study Evaluating the Use of J-Plasma® for Dermal Resurfacing
Verified date | July 2022 |
Source | Apyx Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the safety and effectiveness of J-Plasma in the reduction of facial wrinkles and rhytides. It is a multi-center, single arm, evaluator-blind prospective study of 55 study subjects who are seeking a procedure to reduce the appearance of wrinkles and rhytides and will be conducted at up to 5 investigational centers in the United States. Each study subject will receive one procedure with J-Plasma at enrollment. Follow-up will occur immediately following the procedure, at 10 days, 1, 3, and 6 months after enrollment.
Status | Completed |
Enrollment | 55 |
Est. completion date | November 16, 2018 |
Est. primary completion date | August 20, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: 1. Male or female subjects =30 years of age. 2. Subject is seeking improvement of facial appearance by reducing facial wrinkles and rhytides. 3. Subject with a facial wrinkle score rating of at least 2 on the FWS as determined by the investigator. 4. Subject with a Fitzpatrick Skin Scale score =III. 5. Subject is willing and able to provide written informed consent. 6. Subject is willing and able to comply with protocol requirements, including obtaining study-required images/photos and assessments, and returning for follow-up visits. 7. Subject is willing to release rights to study Sponsor for the use of the photos, including in potential publication. 8. Subject is willing to abstain from other facial cosmetic procedures through the 6 month follow-up visit; examples include, but are not limited to, laser or chemical re-surfacing, dermabrasion, neuromodulator and/or filler injections, aesthetic facial surgery, etc. Exclusion Criteria: 1. Subject with a Fitzpatrick Skin Scale score >III. 2. Subject is pregnant or lactating. 3. Active HSV-1 or diabetes mellitus. 4. Active cut, wound, or infection on the skin of the face. 5. Subject has used, within the past 30 days, Accutane or any medication that can cause dermal hypersensitivity. 6. Subject has a history of autoimmune disease. 7. Subject with a bleeding disorder or who is on blood thinning medication that may be at risk for bleeding. 8. Subject has a known adverse reaction to anesthetics. 9. Subjects with active skin disease of the facial area or known connective tissue disease. 10. Subjects with known susceptibility to keloid formation or hypertrophic scarring. 11. Subjects with present cancerous or pre-cancerous lesions in the area to be treated. 12. Subject who, for any reason, suspects that they will not be able to complete the prescribed follow-up assessment(s); 13. Subject has had concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety and efficacy of the study treatment method. 14. Subject is not willing to release rights to study Sponsor for the use of the photos, including in potential publication. 15. Subject is enrolled in another investigational (drug or device) clinical trial that can interfere with this study's assessments. 16. Subject has undergone a facelift procedure or received facial injections within the past year. |
Country | Name | City | State |
---|---|---|---|
United States | Atlanta Dermatology, Vein & Research Center | Alpharetta | Georgia |
United States | Miami Plastic Surgery | Miami | Florida |
United States | Institute for Integrated Aesthetics | Sarasota | Florida |
Lead Sponsor | Collaborator |
---|---|
Apyx Medical |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of Participants With an Improvement on the FWS (as Scored by Independent Reviewers) and Modified GAIS Scale (as Scored by Participants) at 3 Months | Fitzpatrick Wrinkle and Elastosis Scale (FWS) = 1-score improvement and = 75% agreement with at least an "improved" rating by the subject on the modified Global Aesthetic Improvement Scale (GAIS) at 3 months compared to baseline. FWS Scale: Min=1, Max=9, where 1 is best and 9 is worst. The larger the difference between the baseline and 3 month scores, the greater the improvement. Modified GAIS Scale ratings: "Very much improved," "Much improved," "Improved," "No change," "Worse," "Much worse," and "Very much worse." An "improvement" on the modified GAIS includes "Improved," "Much improved," or "Very much improved." | Baseline to 3 months | |
Other | Mean Change in Fitzpatrick Wrinkle and Elastosis Scale (FWS) From Baseline to 3-month Follow-up Visit | Magnitude of improvement measured by the mean change in Fitzpatrick Wrinkle and Elastosis Scale (FWS) from baseline to 3-month visit. Scale of 1 to 9 where 1 represents the lowest severity of wrinkles and 9 represents the greatest severity of wrinkles. Negative change value represents aesthetic improvement. | Baseline to 3 months | |
Other | Study Subject Satisfaction at 3-month Visit | Evaluation of the subject satisfaction as reported by the subject on a visual analog scale (VAS). VAS scale ranges 0-10, 0 = best possible level of satisfaction, 10= worst possible level of satisfaction | 3 Months | |
Other | Achievement of Re-epithelialization - 10 Days | Achievement of re-epithelialization by facial zone and across facial zones after treatment | 10 Days | |
Other | Achievement of Re-epithelialization - 1 Month | Achievement of re-epithelialization by facial zone and across facial zones after treatment | 1 Month | |
Other | Achievement of Re-epithelialization - 3 Months | Achievement of re-epithelialization by facial zone and across facial zones after treatment | 3 Months | |
Other | Mean Duration for Study Subject to Feel Comfortable in Public After Treatment | Mean duration for study subject to feel comfortable in public after treatment as reported by the subject | Up to 3 months | |
Other | Study Subject - Pain/Discomfort Daily 10-point Visual Analog Scale (VAS) Pre-procedure, Post-procedure, and Daily Through the 10 Day Follow-up Visit (10d FUV Visit Window: 9-14 Days) | Daily 10-point Visual Analog Scale (VAS) pain assessments following treatment through the 10 day follow-up visit by diary day with a change from the VAS pain score at baseline. The 10 day follow-up visit window was 9-14 days. Not all participants recorded their VAS score every day on the daily diary; daily diary was collected from each participant at their 10 day follow-up visit (visit window: 9-14 days). | Pre-procedure, post-procedure and Daily through 10 Day Follow-up Visit, approximately 9-14 days | |
Other | Proportion of Subjects With Correct Identification of 3-month Images | The proportion of subjects (i.e. percentage of treatment responders) with correct identification of 3-month images, in comparison to baseline, as determined by at least 2 out of 3 blinded Independent Photographic Reviewers. | Baseline to 3 months | |
Primary | Improvement in Fitzpatrick Wrinkle and Elastosis Scale (FWS) Score | The comparison of the proportion of subjects (i.e. percentage of treatment responders) with a = 1-score improvement on the FWS at the 3-month visit, as compared to baseline as determined by at least 2 out of 3 blinded Independent Photographic Reviewers. Min=1, Max=9, where 1 is best and 9 is worst. The larger the difference between the baseline and 3 month scores, the greater the improvement. | Baseline to 3 months | |
Primary | Adverse Event Rate and Duration | Adverse event rates, categorized by duration | Up to 3 months | |
Secondary | Number of Participants With a = 1-score Improvement on the Fitzpatrick Wrinkle and Elastosis Scale (FWS) and at Least an "Improved" Rating on the Modified Global Aesthetic Improvement Scale (GAIS) at the 3-month Visit. | Assessment of modified Global Aesthetic Improvement Scale (GAIS) at the 3-month visit compared to baseline as assessed by the investigator. Scale ratings: "Very much improved," "Much improved," "Improved," "No change," "Worse," "Much worse," and "Very much worse." An "improvement" on the modified GAIS includes "Improved," "Much improved," or "Very much improved." | Baseline to 3 months | |
Secondary | Evaluation of Pain and Discomfort | The evaluation of the pain and discomfort after treatment as reported by the subject on a 10-point visual analog scale (VAS). Mean change in VAS from baseline to 3 months. 0 = best possible level of pain and discomfort, 10= worst possible level of pain and discomfort. | Baseline to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00978887 -
Retorna Facial Cream in the Treatment of Facial Wrinkles
|
Phase 3 | |
Completed |
NCT00414544 -
Evaluation of the Safety and Efficacy of CosmetaLifeā¢ for the Correction of Nasolabial Folds
|
Phase 2 | |
Completed |
NCT00888914 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
Completed |
NCT00877279 -
Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft
|
Phase 3 | |
Completed |
NCT01124565 -
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
Completed |
NCT00922623 -
Safety and Effectiveness of Belotero® in Subjects With Fitzpatrick Phototypes IV Through VI
|
N/A | |
Not yet recruiting |
NCT03836638 -
The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment
|
N/A | |
Not yet recruiting |
NCT06322875 -
A Clinical Study to Evaluate the Efficacy and Satisfaction of RHC Serum Combined With RHC(III) Injection
|
N/A | |
Completed |
NCT01566396 -
Evaluation of Safety and Efficacy of the 3F Applicator (A3F) for Treatment of Facial Wrinkles
|
N/A | |
Completed |
NCT01151436 -
Global Management of Facial Rejuvenation With a New Range of Hyaluronic Acid Dermal Fillers
|
N/A | |
Completed |
NCT06321770 -
Oral Supplementation With Active Collagen Peptides and Skin Health Improvement
|
N/A | |
Completed |
NCT01379365 -
Cryo-Touch III Refinement Study Investigational Plan
|
Phase 2/Phase 3 | |
Completed |
NCT00288470 -
A Double-blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast.
|
N/A | |
Completed |
NCT02122536 -
Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles
|
N/A | |
Completed |
NCT01167140 -
Cryo-Touch II for the Treatment of Wrinkles
|
Phase 2/Phase 3 | |
Completed |
NCT00968825 -
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
|
Phase 2 | |
Completed |
NCT01064518 -
Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults
|
Phase 2 | |
Completed |
NCT00417469 -
A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)
|
Phase 3 | |
Completed |
NCT00293163 -
A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.
|
Phase 4 |